3-[(Carbamoyloxy)methyl]-7-[2-(furan-2-yl)-2-(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酰胺类
• 英文名称: 3-[(Carbamoyloxy)methyl]-7-[2-(furan-2-yl)-2-(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
• 英文别名: 3-(carbamoyloxymethyl)-7-[[(2E)-2-(furan-2-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
• 化学式: C₁₆H₁₆N₄O₈S
• 分子量: 424.4
• InChiKey: JFPVXVDWJQMJEE-DJKKODMXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  29
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  199
• 氢给体数：
  3
• 氢受体数：
  10

ADMET

毒理性

• 在妊娠和哺乳期间的影响

◉ 母乳喂养期间使用总结：有限的信息表明，头孢呋辛在乳汁中产生低水平，预计不会对哺乳婴儿造成严重的不良影响。单独使用头孢呋辛似乎不会改变乳汁的菌群，但它可能会改变婴儿的大便菌群。偶尔有报道称使用头孢菌素会导致腹泻或鹅口疮，但这些影响尚未得到充分评估。头孢呋辛在哺乳母亲中是可以接受的。 ◉ 对哺乳婴儿的影响：一项前瞻性、对照研究询问了致电信息服务的母亲，关于她们哺乳婴儿经历的不良反应。母亲们正在服用头孢氨苄或头孢呋辛。两组在不良反应发生率上没有发现统计学差异，每组有1例腹泻。这相当于暴露于头孢呋辛的婴儿中有2.6%。 ◉ 对泌乳和乳汁的影响：截至修订日期，没有找到相关的已发布信息。

◉ Summary of Use during Lactation:Limited information indicates that cefuroxime produces low levels in milk that are not expected to cause severe adverse effects in breastfed infants. Cefuroxime does not appear to alter the flora of breastmilk when used alone, but it can alter the infant’s fecal flora. Occasionally, diarrhea or thrush have been reported with cephalosporins, but these effects have not been adequately evaluated. Cefuroxime is acceptable in nursing mothers. ◉ Effects in Breastfed Infants:A prospective, controlled study asked mothers who called an information service about adverse reactions experience by their breastfed infants. Mothers were taking either cephalexin or cefuroxime. No statistical difference was found in the rate of adverse reactions in the 2 groups, with 1 case of diarrhea in each. This amounted to 2.6% of the cefuroxime-exposed infants. ◉ Effects on Lactation and Breastmilk:Relevant published information was not found as of the revision date.

来源:Drugs and Lactation Database (LactMed)

文献信息

• Carboxylic acid esters of pharmaceutical compounds
  申请人：Ascher Gerd

  公开号：US20060122164A1

  公开（公告）日：2006-06-08

  A pharmaceutically active compound having a carboxylic acid group —COOH as a part of its chemical structure which —COOH group is in the form of a carboxylic acid ester.

  一种具有羧酸基—COOH作为其化学结构的药物活性化合物，其中—COOH基团以羧酸酯的形式存在。
• Process for the preparation of crystalline cefuroxime axetil
  申请人：——

  公开号：US20040242864A1

  公开（公告）日：2004-12-02

  The present invention relates to a process for the preparation of crystalline cefuroxime axetil with high purity lecel and optimal diastereomeric ratio. Said process, which comprises the use of a dimethyl carbonate for isolating crystallizing cefuroxime axetil, is particularly suitable for implementing on an industrial scale.

  本发明涉及一种制备高纯度头孢呋辛酯和最佳非对映异构体比率的结晶头孢呋辛酯的工艺。该工艺包括使用碳酸二甲酯来分离结晶头孢呋辛酯，特别适合工业化生产。
• CARBOXYLIC ACID ESTERS OF PHARMACEUTICAL COMPOUNDS
  申请人：SANDOZ AG

  公开号：EP1590354A2

  公开（公告）日：2005-11-02
• TRANSDERMAL DELIVERY SYSTEMS OF BETA-LACTAM ANTIBIOTICS
  申请人：Yu, Chongxi

  公开号：EP2121593A1

  公开（公告）日：2009-11-25
• COMPOSITIONS AND MEANS FOR DIAGNOSING MICROBIAL INFECTIONS
  申请人：Statens Serum Institut

  公开号：EP2181330B1

  公开（公告）日：2013-11-20